Overactivation of the renin-angiotensin-aldosterone system (RAAS) has been implicated in the development and progression of diabetic nephropathy, and ARB/ACE inhibitor blockade is currently the mainstay of treatment [145]. The gene discussed is ACE; the disease is diabetic kidney disease.